Estimated longevity benefit: +1.0 years. Evidence score: 64/100.
Acarbose is an alpha-glucosidase inhibitor that slows the breakdown of complex carbohydrates to blunt post-meal glucose and insulin spikes. By reducing the cumulative metabolic burden and insulin signaling, it addresses a primary driver of aging and has demonstrated up to 22% median lifespan extension in rigorous animal testing.
Acarbose is a competitive inhibitor of alpha-glucosidase — the intestinal enzyme that breaks down complex carbohydrates into absorbable sugars. By slowing this step, acarbose blunts the post-meal glucose spike and the corresponding insulin surge, reducing chronic insulin signaling that is increasingly recognized as a driver of biological aging. The primary longevity mechanism involves the mitigation of post-prandial hyperinsulinemia, which otherwise drives pro-aging pathways like mTOR and IGF-1. Additionally, the delivery of undigested starch to the colon promotes a more diverse, butyrate-producing microbiome, further enhancing systemic metabolic health and reducing age-related inflammation.
The ITP Evidence (the Gold Standard): The NIA Interventions Testing Program tested acarbose across three independent laboratories using genetically diverse UM-HET3 mice — the closest animal model to human genetic diversity. Results were dramatic and consistent: - +22% median lifespan in males at 1000 ppm (started at 4 months of age) - +5% median in females — statistically significant but sex-asymmetric - +11% maximum lifespan extension in males — meaning even the longest-lived mice benefited - The effect held across multiple doses (400, 1000, and 2500 ppm) and even when treatment began at 16 months of age (roughly equivalent to a 55-year-old human)
This makes acarbose one of the most robustly replicated longevity compounds ever tested in animals. The ITP is specifically designed to eliminate false positives: if something works there, it works for real.
Mechanism — Two Aging Pathways at Once: Acarbose targets metabolic aging through several overlapping mechanisms: 1. Reduced chronic hyperinsulinemia: Post-meal insulin spikes, repeated over decades, accelerate cellular aging through chronic IGF-1 and mTOR activation. Acarbose blunts this. 2. Glucose buffering: By smoothing glucose curves, acarbose reduces glycation of proteins and DNA — a direct aging mechanism (advanced glycation end-products, or AGEs). 3. Microbiome reshaping: Undigested carbohydrates that reach the colon act as prebiotics, increasing butyrate-producing bacteria. Butyrate is a HDAC inhibitor with anti-inflammatory and epigenetic-regulatory properties. 4. GLP-1 enhancement: Slower glucose absorption increases the stimulus for GLP-1 secretion from L-cells in the small intestine, improving metabolic signaling that mimics some benefits of caloric restriction.
The Combination Effect: In Strong et al. (2022), acarbose combined with rapamycin produced a +37% median lifespan extension in males — the largest effect the ITP has ever documented. This suggests acarbose and rapamycin hit complementary aging pathways (mTOR inhibition + glucose metabolism), producing a synergistic effect greater than either alone.
Human Translation Caveats: All ITP data is from mice. The sex asymmetry (22% in males vs. 5% in females) is unexplained but consistent across doses and cohorts. Acarbose is FDA-approved for type 2 diabetes, is generic and inexpensive (~$15-30/month), and has a well-established human safety profile over decades of use. Its primary side effects (bloating, flatulence) are dose-dependent and caused by fermentation of undigested carbohydrates in the colon — they typically diminish with low-and-slow titration. The biological mechanism relies on its ability to lower the glycemic index of meals, thereby reducing the cumulative burden of glucose-driven oxidative stress and inflammation. Evidence is exceptionally strong in animal models for lifespan extension, while human evidence is currently focused on metabolic health improvements in diabetic and pre-diabetic populations. A key nuance is that the life-extending benefits in mice were far more pronounced in males, a finding that requires further investigation to understand its applicability to human females.
Critical Warning: While acarbose is a widely used pharmaceutical for diabetes management, its application for longevity in healthy individuals is considered experimental. Any use should be guided by a medical professional to monitor for potential side effects and ensure it does not interfere with other health conditions or medications. - Acarbose is FDA-approved for type 2 diabetes but NOT approved for longevity use - Off-label longevity use requires physician supervision and baseline metabolic panel - Contraindicated in: inflammatory bowel disease, bowel obstruction, cirrhosis, renal impairment (CrCl <25 ml/min) - Does NOT cause hypoglycemia when used as monotherapy (no insulin secretion effect)
How Acarbose Works — Why Titration Is Non-Negotiable: The effectiveness of acarbose depends on its ability to inhibit the breakdown of starches into glucose within the intestine. Because this results in more undigested carbohydrates reaching the colon, a gradual increase in dosage is essential to allow the gut microbiome to adapt and minimize gastrointestinal discomfort. Undigested carbohydrates reaching the colon are fermented by gut bacteria, producing gas (CO2, H2, methane). Starting at a full dose causes severe bloating and flatulence that makes adherence nearly impossible. A slow 4–8 week titration allows the gut microbiome to adapt.
Standard Longevity Titration Protocol: Implementing a structured titration schedule helps the digestive system adjust to the presence of unabsorbed carbohydrates while maximizing the metabolic benefits of the intervention. This progressive approach ensures that users can reach therapeutic doses without significant disruption to their daily lives. - Week 1–2: 25mg once daily with largest meal - Week 3–4: 25mg with two meals per day - Week 5–6: 50mg with two meals per day - Week 7–8: 50mg with each of three meals per day (maximum longevity dose) - Some physicians use 25mg three times daily as a maintenance dose to minimize GI side effects
Timing Is Critical: The pharmacodynamics of acarbose require it to be present in the small intestine at the exact moment carbohydrate digestion begins. Proper timing is the most important factor in ensuring the drug effectively blunts the glucose spike from a meal. - Take at the FIRST BITE of each meal — not before or after - The drug must be present when alpha-glucosidase enzymes are activated - No benefit if taken outside meal windows
Dietary Considerations: While acarbose is effective at slowing carbohydrate digestion, its impact is most pronounced when paired with a diet that already emphasizes whole, low-glycemic foods. Understanding how different macronutrients interact with the drug can help users refine their nutritional strategy for better metabolic control. - Effects are greatest with high-carbohydrate meals; minimal effect if eating keto/very-low-carb - Allows more liberal carbohydrate intake if following low-glycemic principles - Consider continuous glucose monitoring (CGM) to verify glucose blunting is occurring
Monitoring: - Fasting glucose and HbA1c: Confirm metabolic benefit (target HbA1c <5.7%) - Post-meal glucose (with CGM ideally): Target peak <140 mg/dL, ideally <120 mg/dL - Liver enzymes (ALT/AST): Baseline and at 6 months — rare reports of elevated LFTs at high doses - Ferritin and iron: Rare reports of reduced iron absorption with long-term use
Combination Considerations: - Rapamycin + Acarbose: The strongest ITP combination ever tested. If using both, begin with established doses of each before combining - Compatible with metformin (complementary mechanisms — acarbose is pre-absorptive, metformin is post-absorptive) - Reduces efficacy of amylase-containing digestive enzymes — avoid taking digestive enzymes simultaneously
Supports
Strong R, Miller RA, Astle CM, et al.
ITP C2017 cohort: when combined with rapamycin, acarbose produced the largest ever ITP effect (+37% males, +28% females). Confirms acarbose hits a complementary aging pathway to mTOR inhibition.
View paperSupports
Jiang N, Xu Z, Zhao S, et al.
Comprehensive 20-year review of ITP data confirming acarbose's robust lifespan extension and placing it in context of the sex-differential response pattern observed across ITP compounds.
View paperSupports
Strong R, Miller RA, Antebi A, et al.
ITP replication of acarbose lifespan extension across multiple doses and an independent cohort, confirming the sex-specific effect. Also first test of 17α-estradiol showing +19% median lifespan in males.
View paperQuestions
van de Laar FA, Lucassen PL, Akkermans RP, et al.
All longevity evidence for acarbose is from mouse models. Human trials in type 2 diabetics show modest glucose-lowering but no longevity endpoint data. GI side effects (flatulence, bloating) are common.
View paperSupports
Harrison DE, Strong R, Allison DB, et al.
First ITP test of acarbose: +22% median lifespan in males at 1000 ppm. Female effect was smaller (+5%) but statistically significant. Both median and maximum lifespan extended in males.
View paper